查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
亚太地区细胞与基因治疗製造品质控制市场：分析与预测（2023-2033）
市场调查报告书
商品编码
1416208

亚太地区细胞与基因治疗製造品质控制市场：分析与预测（2023-2033）

Asia-Pacific Cell and Gene Therapy Manufacturing QC Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 101 Pages | 商品交期: 1-5个工作天内

价格
主要市场统计数据
预测期 2023-2033
2023年评估 4.263 亿美元
2033年预测 22.336 亿美元
复合年增长率 18.01%

2023 年，亚太地区细胞和基因治疗製造品质控制市场规模达 4.263 亿美元。

预计到 2033 年，市场规模将达到 22.336 亿美元，2023-2033 年预测期间复合年增长率为 18.01%。由于核准治疗方法的增加以及基础设施扩张的需求，细胞和基因疗法製造 QC (QC) 市场预计将成长。此外，细胞和基因疗法针对的多种病理需要广泛的製造和品质控制流程，从而促进市场成长。

亚太地区的细胞和基因治疗製造品质控制 (QC) 市场正在经历显着成长。这一市场扩张背后有几个因素，包括先进疗法的采用增加、生物技术和製药行业投资的增加以及熟练劳动力的存在。此外，该地区慢性病盛行率的不断上升正在加速对创新细胞和基因疗法的需求，从而需要严格的品质控制措施。新兴国家正积极参与研发活动并促进与生技公司的合作。因此，亚太地区的细胞和基因治疗製造品质控制市场预计在未来几年将显着增长，从而促进该地区医疗保健解决方案的发展。

本报告探讨了亚太地区细胞和基因治疗製造品质控制市场，提供了市场概述、按治疗类型、产品、工艺、应用、技术、国家和进入市场的公司分類的趋势。我们提供简介等。

目录

执行摘要

第一章 市场

  • 产品定义
  • 调查方法
  • 市场概况
    • 市集情境
    • 市场足迹和成长潜力
    • 未来性
    • COVID-19 对市场的影响

第二章细胞/基因治疗製造QC市场：产业分析

  • 法律规范
    • 食品药物管理局(FDA) 的化学、製造和控制 (CMC) 要求
    • 欧洲药品管理局 (EMA) 的细胞和基因治疗产品品质方面
    • 现行良好生产规范 (CGMP) 法规
    • 法律规范：细胞和基因治疗製造品质控制市场

第三章 细胞/基因治疗製造QC市场（按地区）

  • 概述
  • 亚太地区
    • 中国
    • 日本
    • 韩国
    • 澳洲
    • 印度
    • 其他地区

第四章 公司简介

Product Code: BHP1817SS

“The Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Expected to Reach $2,233.6 Million by 2033.”

Introduction to Asia-Pacific Cell and Gene Therapy Manufacturing QC Market

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$426.3 Million
2033 Forecast$2,233.6 Million
CAGR18.01%

The Asia-Pacific cell and gene therapy manufacturing QC market was valued at $426.3 million in 2023 and is expected to reach $2,233.6 million by 2033, growing at a CAGR of 18.01% during the forecast period 2023-2033. The cell and gene therapy manufacturing quality control (QC) market is projected to grow due to the rising number of approved therapies and the need for expanded infrastructure. Furthermore, the broader range of medical conditions targeted by cell and gene therapies necessitates large-scale manufacturing and QC processes, contributing to market growth.

Market Introduction

The Asia-Pacific (APAC) region is witnessing significant growth in the cell and gene therapy manufacturing quality control (QC) market. This expansion is driven by several factors, including the rising adoption of advanced therapies, increasing investments in biotechnology and pharmaceutical sectors, and the presence of a skilled workforce. Moreover, the growing prevalence of chronic diseases in the region has accelerated the demand for innovative cell and gene therapies, necessitating stringent QC measures. APAC countries are actively involved in research and development activities, fostering collaborations with biotech companies. As a result, the APAC cell and gene therapy manufacturing QC market is poised for substantial growth in the coming years, contributing to the advancement of healthcare solutions in the region.

Market Segmentation

Segmentation 1: by Therapy Type

  • Cell Therapy
  • Gene Therapy

Segmentation 2: by Offering

  • Products
  • Services

Segmentation 3: by Process

  • Raw Material Preparation
  • Upstream Processing
  • Downstream Processing
  • Packaging

Segmentation 4: by Application

  • Safety Testing
  • Potency Testing
  • Identity Testing
  • Stability and Genetic Fidelity Testing
  • Others

Segmentation 5: by Technology

  • Polymerase Chain Reaction (PCR)
  • Flow Cytometry
  • Limulus Amebocyte Lysate (LAL)
  • Enzyme-Linked Immunosorbent Assay (ELISA)
  • Chromatography
  • Mass Spectrometry
  • Western Blotting
  • Next-Generation Sequencing (NGS)
  • Electrophoresis
  • Other Technologies

Segmentation 6: by Country

  • China
  • Japan
  • South Korea
  • Australia
  • India
  • Rest-of-Asia-Pacific and Japan

How can this report add value to an organization?

Workflow/Innovation Strategy: The APAC cell and gene therapy manufacturing QC market (by offering) has been segmented into products and services. Moreover, the study provides the reader with a detailed understanding of the different applications of cell and gene therapy manufacturing QC in raw material preparation, upstream processing, downstream processing, and packaging.

Growth/Marketing Strategy: Cell and gene therapy manufacturing QC is being used for raw material preparation, upstream processing, downstream processing, and packaging. Various companies are providing products and services to aid in the manufacturing and QC of various cell and gene therapies, which is also the key strategy for market players to excel in the current APAC cell and gene therapy manufacturing QC market.

Competitive Strategy: Key players in the APAC cell and gene therapy manufacturing QC market have been analyzed and profiled in the study, including manufacturers involved in new product launches, acquisitions, expansions, and strategic collaborations. Moreover, a detailed competitive benchmarking of the players operating in the APAC cell and gene therapy manufacturing QC market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Product Definition
    • 1.1.1. Product Definition
    • 1.1.2. Inclusion and Exclusion Criteria
  • 1.2. Market Scope
    • 1.2.1. Key Questions Answered in the Report
  • 1.3. Research Methodology
    • 1.3.1. Cell and Gene Therapy Manufacturing QC Market
    • 1.3.2. Data Sources
      • 1.3.2.1. Primary Data Sources
      • 1.3.2.2. Secondary Data Sources
    • 1.3.3. Market Estimation Model
    • 1.3.4. Criteria for Company Profiling
  • 1.4. Market Overview
    • 1.4.1. Market Scenario
      • 1.4.1.1. Realistic Growth Scenario
      • 1.4.1.2. Optimistic Scenario
      • 1.4.1.3. Pessimistic Scenario
    • 1.4.2. Market Footprint and Growth Potential
    • 1.4.3. Future Potential
    • 1.4.4. COVID-19 Impact on Market
      • 1.4.4.1. Impact on Research and Clinical Operations
      • 1.4.4.2. COVID-19 Impact: Current Scenario of the Market
      • 1.4.4.3. Pre- and Post-COVID-19 Impact Assessment
        • 1.4.4.3.1. Pre-COVID-19 Phase
        • 1.4.4.3.2. Post-COVID-19 Phase

2. Cell and Gene Therapy Manufacturing QC Market: Industry Analysis

  • 2.1. Regulatory Framework
    • 2.1.1. Chemistry, Manufacturing, and Control (CMC) Requirements by the Food and Drug Administration (FDA)
      • 2.1.1.1. Product Testing
      • 2.1.1.2. Microbial Testing
      • 2.1.1.3. Identity
      • 2.1.1.4. Purity
      • 2.1.1.5. Potency
      • 2.1.1.6. Viability
      • 2.1.1.7. Cell Number or Dose
    • 2.1.2. Quality Aspects of Cell and Gene Therapy Products by the European Medicines Agency (EMA)
      • 2.1.2.1. Characterization
      • 2.1.2.2. Identity Testing
      • 2.1.2.3. Purity Testing
    • 2.1.3. Current Good Manufacturing Practice (CGMP) Regulations
    • 2.1.4. Regulatory Framework: Cell and Gene Therapy Manufacturing QC Market

3. Cell and Gene Therapy Manufacturing QC Market (by Region)

  • 3.1. Overview
  • 3.2. Asia-Pacific
      • 3.2.1.1. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.1.2. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.1.3. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.1.4. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.1.5. Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.2. China
      • 3.2.2.1. China Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.2.2. China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.2.3. China Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.2.4. China Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.2.5. China Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.3. Japan
      • 3.2.3.1. Japan Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.3.2. Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.3.3. Japan Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.3.4. Japan Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.3.5. Japan Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.4. South Korea
      • 3.2.4.1. South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.4.2. South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.4.3. South Korea Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.4.4. South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.4.5. South Korea Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.5. Australia
      • 3.2.5.1. Australia Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.5.2. Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.5.3. Australia Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.5.4. Australia Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.5.5. Australia Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.6. India
      • 3.2.6.1. India Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.6.2. India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.6.3. India Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.6.4. India Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.6.5. India Cell and Gene Therapy Manufacturing QC Market (by Application)
    • 3.2.7. Rest-of-Asia-Pacific
      • 3.2.7.1. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering)
      • 3.2.7.2. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type)
      • 3.2.7.3. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process)
      • 3.2.7.4. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology)
      • 3.2.7.5. Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application)

4. Company Profiles

  • 4.1. Overview
  • 4.2. Manufacturers
    • 4.2.1. WuXi AppTec
      • 4.2.1.1. Company Overview
      • 4.2.1.2. Role of WuXi AppTec in the Cell and Gene Therapy Manufacturing QC Market
      • 4.2.1.3. Key Competitors
      • 4.2.1.4. Financials
      • 4.2.1.5. Analyst Perspective

List of Figures

  • Figure 1: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 2: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, Impact Analysis
  • Figure 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), % Share, 2022 and 2033
  • Figure 4: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), % Share, 2022 and 2033
  • Figure 5: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), % Share, 2022 and 2033
  • Figure 6: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), % Share, 2022 and 2033
  • Figure 7: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), % Share, 2022 and 2033
  • Figure 8: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 9: Cell and Gene Therapy Manufacturing QC Market: Research Methodology
  • Figure 10: Primary Research Methodology
  • Figure 11: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 12: Top-Down Approach (Segment-Wise Analysis)
  • Figure 13: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Realistic Scenario), $Billion, 2022-2033
  • Figure 14: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Optimistic Scenario), $Billion, 2022-2033
  • Figure 15: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Size and Growth Potential (Pessimistic Scenario), $Billion, 2022-2033
  • Figure 16: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Billion, 2022-2033
  • Figure 17: Impact of COVID-19 on CGT Developmental Activities
  • Figure 18: Cell and Gene Therapy Manufacturing QC Market (by Region), Market Snapshot
  • Figure 19: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 20: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Country), % Share, 2022-2033
  • Figure 21: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 22: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 23: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 24: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 25: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 26: China Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 27: China Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 28: China Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 29: China Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 30: China Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 31: China Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 32: Japan Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 33: Japan Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 34: Japan Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 35: Japan Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 36: Japan Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 37: Japan Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 38: South Korea Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 39: South Korea Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 40: South Korea Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 41: South Korea Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 42: South Korea Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 43: South Korea Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 44: Australia Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 45: Australia Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 46: Australia Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 47: Australia Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 48: Australia Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 49: Australia Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 50: India Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 51: India Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 52: India Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 53: India Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 54: India Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 55: India Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 56: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market, $Million, 2022-2033
  • Figure 57: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Offering), $Million, 2022-2033
  • Figure 58: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Therapy Type), $Million, 2022-2033
  • Figure 59: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Process), $Million, 2022-2033
  • Figure 60: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Technology), $Million, 2022-2033
  • Figure 61: Rest-of-Asia-Pacific Cell and Gene Therapy Manufacturing QC Market (by Application), $Million, 2022-2033
  • Figure 62: Total Number of Companies Profiled
  • Figure 63: WuXi AppTec: Product Portfolio
  • Figure 64: WuXi AppTec: Overall Financials, $Million, 2020-2022
  • Figure 65: WuXi AppTec: Revenue (by Segment), $Million, 2021 and 2022

List of Tables

  • Table 1: Key Questions Answered in the Report
  • Table 2: Regulatory Scenario: Cell and Gene Therapy Manufacturing QC Market
  • Table 3: Asia-Pacific Cell and Gene Therapy Manufacturing QC Market Dynamics, Impact Analysis
  • Table 4: Approved Cell and Gene Therapies, Japan